WESTON, Fla., Oct. 16, 2018 /PRNewswire/ -- Variant
Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug
company developing first-in-class drugs for patients with rare
diseases, announced today Notice of Allowance for two U.S. patent
applications covering hydroxypropyl-β-cyclodextrin (HPβCD) for use
in renal diseases (licensed from L&F Research LLC). Variant's
HPβCD pipeline includes VAR 200, a phase 2a-ready asset in
development for FSGS; VAR 300 for Alport Syndrome, and VAR 400 for
Diabetic Kidney Disease.
The claims in U.S. patent application 14/967,831 relate to use
of HPβCD to treat FSGS and Alport Syndrome, reduce progression of
FSGS, and reduce recurrence of FSGS following transplant.
The claims in U.S. patent application 14/391,236 relate to use
of HPβCD or its derivatives to treat or reduce progression of
Diabetic Kidney Disease.
"These Notices of Allowance strengthen the value of Variant's
pipeline with intellectual property protection, and they highlight
our progress toward development and commercialization of novel drug
therapies to optimize patient outcomes," stated Stephen C. Glover, Variant's Co-founder,
Chairman and Chief Executive Officer. "Through ongoing research and
development, we will continue to advance our intellectual property
estate by pursuing broader and/or modified scopes of
protection."
About Variant
Variant Pharmaceuticals, a clinical stage orphan drug company
focusing on restoring health and transforming the lives of patients
with rare diseases through innovation, was established in 2014,
with the mission to become a leading orphan drug company. Our
evolving product pipeline is targeted to the $100+ billion orphan
drug market. Our lead drug candidate is
2-hydroxypropyl-β-cyclodextrin (2HPβCD) for chronic treatment of
two rare kidney indications, Focal Segmental Glomerulosclerosis
(FSGS) and Alport Syndrome (AS), which have an addressable market
greater than $3.5 Billion.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/variant-pharmaceuticals-receives-notice-of-allowance-in-two-us-patent-applications-covering-lead-compound-2-hydroxypropyl--cyclodextrin-a-phase-2a-ready-asset-for-rare-renal-disease-focal-segmental-glomerulosclerosis-fsgs-300731618.html
SOURCE Variant Pharmaceuticals, Inc.